These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20823097)

  • 1. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function.
    Ponikowski P; Mitrovic V; O'Connor CM; Dittrich H; Cotter G; Massie BM; Givertz MM; Chen E; Murray M; Weatherley BD; Fujita KP; Metra M
    Eur J Heart Fail; 2010 Nov; 12(11):1238-46. PubMed ID: 20823097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
    Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
    Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
    N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
    Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
    Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
    Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.
    Metra M; O'Connor CM; Davison BA; Cleland JG; Ponikowski P; Teerlink JR; Voors AA; Givertz MM; Mansoor GA; Bloomfield DM; Jia G; DeLucca P; Massie B; Dittrich H; Cotter G
    Eur Heart J; 2011 Jun; 32(12):1519-34. PubMed ID: 21388992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
    Teerlink JR; Iragui VJ; Mohr JP; Carson PE; Hauptman PJ; Lovett DH; Miller AB; Piña IL; Thomson S; Varosy PD; Zile MR; Cleland JG; Givertz MM; Metra M; Ponikowski P; Voors AA; Davison BA; Cotter G; Wolko D; Delucca P; Salerno CM; Mansoor GA; Dittrich H; O'Connor CM; Massie BM
    Drug Saf; 2012 Mar; 35(3):233-44. PubMed ID: 22339573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
    Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM
    J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
    Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
    J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study.
    Greenberg B; Thomas I; Banish D; Goldman S; Havranek E; Massie BM; Zhu Y; Ticho B; Abraham WT
    J Am Coll Cardiol; 2007 Aug; 50(7):600-6. PubMed ID: 17692744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial.
    Demissei BG; Postmus D; Liu LCY; Cleland JG; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Davison BA; Edwards C; Givertz MM; Bloomfield DM; Dittrich HC; Voors AA; Hillege HL
    Int J Cardiol; 2016 Nov; 223():967-975. PubMed ID: 27589047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
    Stroh M; Dishy V; Radziszewski W; Hwang E; Lazarus-Shipitofsky N; Dittrich H; Johnson-Levonas AO; Lutz R; Wagner JA; Lai E
    Am J Ther; 2010; 17(1):53-60. PubMed ID: 20027108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.
    Cotter G; Metra M; Weatherley BD; Dittrich HC; Massie BM; Ponikowski P; Bloomfield DM; O'Connor CM
    Cardiology; 2010; 115(1):29-36. PubMed ID: 19844102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function trajectories and clinical outcomes in acute heart failure.
    Givertz MM; Postmus D; Hillege HL; Mansoor GA; Massie BM; Davison BA; Ponikowski P; Metra M; Teerlink JR; Cleland JG; Dittrich HC; O'Connor CM; Cotter G; Voors AA
    Circ Heart Fail; 2014 Jan; 7(1):59-67. PubMed ID: 24281137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure.
    Gottlieb SS; Ticho B; Deykin A; Abraham WT; Denofrio D; Russell SD; Chapman D; Smith W; Goldman S; Thomas I
    J Clin Pharmacol; 2011 Jun; 51(6):899-907. PubMed ID: 20926754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
    Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
    Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure.
    Kissling KT; Pickworth KK
    Pharmacotherapy; 2014 Aug; 34(8):882-7. PubMed ID: 24990816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.